Skip to main content

Evolus, Inc.

EOLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001570562

In the last 90 days, Evolus, Inc. insiders filed 0 open-market purchases and 1 sale; 169 institutions reported holding it in 13F filings for Q3 2026, worth $405.4M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 20, 2026
$431.5M
Insider buysOpen market, last 90 days
0
Insider sellsLast 90 days, $950.0K in total
1
13F holdersQ3 2026, +13 vs. previous quarter
169
13F valueReported value at the end of Q3 2026
$405.4M
Superinvestors holdingAt the end of Q3 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
$297.2M
+11.6% year over year
Net income, FY2025
-$51.6M
No comparable prior period
Free cash flow, FY2025
-$45.7M
No comparable prior period
Revenue, Q3 FY2026
$78.0M
+13.0% year over year

Revenue flow, FY2025

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2025: $51.6M (17.4% of revenue).

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
6.02M
Shares sold short
Change
−385.7K
−6.0% vs. previous
Days to cover
9.38
At average daily volume

Superinvestors holding EOLS, Q3 2026

Go to the superinvestors tab

No superinvestor reported holding EOLS at the end of Q3 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Evolus, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 4, 2026 (view filing)7:04 PM ETSep 22 daysMoatazedi DavidSee RemarksSSale−105.1K$9.04−$950.0K−17.4%499.6K after
Mar 20, 2026 (view filing)Mar 20Same dayAvelar RuiSee RemarksSSale−3.12K$4.75−$14.8K−0.7%427.4K after
Mar 20, 2026 (view filing)Mar 20Same dayMoatazedi DavidSee RemarksSSale−13.7K$4.75−$64.9K−2.2%604.7K after10b5-1
Mar 18, 2026 (view filing)Mar 171 dayMoatazedi DavidSee RemarksSSale−116.7K$4.89−$570.8K−15.9%618.4K after10b5-1
Mar 18, 2026 (view filing)Mar 171 dayAvelar RuiSee RemarksSSale−30.0K$4.89−$146.7K−6.5%430.5K after10b5-1
Dec 29, 2025 (view filing)Dec 227 daysMoatazedi DavidSee RemarksSSale−10.5K$7.15−$75.4K−2.9%354.4K after10b5-1
Dec 29, 2025 (view filing)Dec 227 daysAvelar RuiSee RemarksSSale−2.26K$7.15−$16.2K−0.6%356.8K after10b5-1
Aug 26, 2025 (view filing)Aug 224 daysYamagishi-Dressler TomokoChief Marketing OfficerSSale−5.72K$7.51−$43.0K−6.0%89.9K after10b5-1
Aug 18, 2025 (view filing)Aug 153 daysStewart BradyDirectorPPurchase+30.0K$6.82+$204.6K+51.2%88.6K after
Jun 16, 2025 (view filing)Jun 13-163 daysMoatazedi DavidSee RemarksSSale−127.9K$10.03−$1.28M−26.0%364.9K after2 lots

Top 10 13F holders, Q3 2026

See all 169 holders

The largest institutional positions in Evolus, Inc. at the end of Q3 2026; share changes are against Q2 2026.

Institutions holding EOLS in Q3 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Nantahala Capital Management, LLC6,244,690$50.0M2.81%+642,669+11.5%Added
BlackRock, Inc.5,315,493$42.5M0.00%+474,665+9.8%Added
Soleus Capital Management, L.P.5,090,000$40.7M1.45%+4,267,572+518.9%Added
Braidwell LP3,084,022$24.7M1.02%−71,187−2.3%Reduced
Frazier Life Sciences Management, L.P.2,630,665$21.0M0.52%00.0%Unchanged
Perceptive Advisors LLC2,459,285$19.7M0.37%00.0%Unchanged
Vanguard Capital Management LLC2,261,324$18.1M0.00%−101,569−4.3%Reduced
State Street Corp1,854,107$14.8M0.00%+156,813+9.2%Added
Millennium Management LLC1,650,372$13.2M0.01%−137,557−7.7%Reduced
Geode Capital Management, LLC1,580,338$12.6M0.00%−28,056−1.7%Reduced

Holders of 5% or more of EOLS

See all 4 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Evolus, Inc..

Largest holders of EOLS from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Lynch Timothy P13G/A9.90%6.43M shares+2.00 ppfrom 7.90%Aug 18, 20253 filingsFeb 17, 2026SEC
Nantahala Capital Management, LLC13G/A8.85%5.73M shares+2.95 ppfrom 5.90%Feb 14, 20244 filingsNov 14, 2025SEC
Soleus Capital Master Fund, L.P.13G/A7.70%5.09M shares+2.40 ppfrom 5.30%Aug 31, 20262 filingsNov 9, 2026SEC
BlackRock, Inc.13G/A6.90%4.36M shares–Feb 5, 20251 filingFeb 5, 2025SEC